BioNMR in drug design

Journal of China Pharmaceutical University

Volumn 35, Issue 5, 2004, Pages 387-392

  Lin, Ke Jiang ^a   You, Qi Dong ^a   Lin, Dong Hai ^b   Wu, Wu Tong ^a   Ye, Bo Ping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

BioNMR; Drug design

Indexed keywords

DIHYDROFOLATE REDUCTASE; LIGAND; METHOTREXATE; NEW DRUG; RNA;

BINDING SITE; BIOMEDICAL TECHNOLOGY ASSESSMENT; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; LIGAND BINDING; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RNA SEQUENCE; STRUCTURE ANALYSIS;

EID: 11344283301     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Shuker SB, Hajduk PJ, Meadows RP, et al. Discovering high-affinity ligands for proteins: SAR by NMR[J]. Science, 1996, 274(5292): 1531-1536.
2. Gargaro AR, Soteriou A, Frenkiel TA, et al. The solution structure of the complex of Lactobacillus casei dihydrofolate reductase with methotrexate[J]. J Mol Biol, 1998,277 1):119-134.
3. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design[J]. Annu Rev Biophys Biomol Struct, 1998,27:249-284.
4. Stockmana BJ, Dalvit C. NMR screening techniques in drug discovery and drug design [J]. Progress in Nuclear Magnetic Resonance Spectroscopy, 2002,41:187-231.
5. Bjerring M, Vosegaard T, Malmendal A, et al. Methodological development of solid-state NMR for characterization of membrane proteins[J]. Concepts in Magnetic Resonance Part A,2003, 18A(2): 111-129.
6. Bak M, Schultz R, Nielsen NC. Numerical simulations for experiment design and extraction of structural parameters in biological solid-state NMR spectroscopy. In: Kiihne SR. de Groot HJM, eds. Perspectives on Solid-State NMR in Biology. Dordrecht [B]. Holland: Kluwer Academic Publishers,2001.95-109.
7. Pochapsky SS, Pochapsky TC. Nuclear magnetic resonance as a tool in drug discovery, metabolism and disposition [J]. Current Topics in Medicinal Chemistry,2001,1(5):427-441.
8. Jardetzky O. Protein dynamics and conformational transitions in allosteric proteins[J]. Prog Biophys Mol Biol, 1996, 65 3): 171-218.
9. Nieto PM, Birdsall B, Morgan WD. Frenkiel TA: correlated bond rotations in interactions of arginine residues with ligand carboxylate groups in protein ligand complexes[J]. FEBS Lett,1977,405 1):16-20.
10. Mark G, Echols N. Exploring the range of protein flexibility, from a structural proteomics perspective[J]. Current Opinion in Chemical Biology,2004,8(1):14-19.
11. Kay LE. Correlation between binding and dynamics at SH2 domain interfaces[J]. Nat Struct Boil,1998,5:156-163.
12. Ben Davis1, Mohammad Afshar1, Gabriele Varani. Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots"[J]. J Mol Biol, 2004,336 2):343-356.
13. Gordon CK, Roberts. Applications of NMR in drug discovery [J]. DDT,2000,5(6):230-240.
14. Murray Coles, Heller M, Kessler H. NMR-based screening technologies[J]. DDT,2003,8(17):803-810
15. Christopher A. Lepre, library design for NMR-based screening[J]. DDT,2001,6(3):133-140.
16. Maria van Dongen, Weigelt J. Structure-based screening and design in drug discovery[J]. DDT,2002,7(8):471-478.